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Abstract: Current lipid management guidelines are focused on decreasing low-density 
lipoprotein (LDL-C) levels as the primary target for reducing coronary heart disease (CHD) 
risk. Yet, many recent studies suggest that low levels of high-density lipoprotein (HDL-C) are 
a major independent risk factor for cardiovascular diseases. According to several clinical trials, 
a 1% increase in HDL-C is associated with a 0.7%–3% decrease in CHD events. The direct link 
between high levels of triglycerides (TG) and CHD, on the other hand, is less well defined. A large 
reduction in TG is needed to show a difference in CHD events, especially in men. Evidence for 
a shift in lipid management toward targeting both LDL-C and HDL-C as primary targets for 
therapy is presented. Currently, the 3-hydroxy-3-methylgutaryl coenzyme A reductase inhibitors 
(HMG-CoA reductase inhibitors) have proven to significantly decrease LDL-C levels, reduce 
CHD morbidity/mortality and improve overall survival. However, improvement of survival with 
statins may be due to other pleiotropic effects beyond LDL-C lowering. Fibric acid derivatives and 
niacin are primarily used to increase HDL-C levels, although with side effects. Future therapies 
targeting HDL-C may have profound results on reducing CHD morbidity and mortality. This 
article highlights existing and future targets in lipid management and is based on available clini-
cal data. There is an urgent need for new treatments using a combination of drugs targeting both 
LDL-C and HDL-C. Such treatments are expected to have a superior outcome for dyslipidemia 
therapy, along with TG management.
Keywords: cholesterol, lipid, LDL-C, HDL-C, triglycerides, statin, nicotinic acid, fibric acid, 
atherosclerosis, coronary heart diseases
Background
Cardiovascular disease (CVD) is the number one cause of death in the United States 
and other industrial nations.1 In 2004, there were about 2.4 million deaths in the United 
States, and of these, approximately 36% were attributed to CVDs such as stroke, acute 
myocardial infarction, atherosclerosis, CHD and pulmonary embolism.1 The economic 
impact of CVDs on the United States healthcare system continues to grow as the popula-
tion ages. The estimated direct and indirect cost of CVD approached US$500 billion in 
2008.1 Thus, CVD is a very costly disease in terms of both human lives and economics. 
There have been major advances in strategies to decrease the incidence of CVD, one of 
which is controlling and improving the lipid profile of patients who are at risk.
The first significant study that associated lipid abnormalities with CVD risk was the 
Framingham Heart Study, which started in 1948. In this study, over ten thousand subjects Vascular Health and Risk Management 2010:6 74
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were enrolled and several risk factors for CVD were identified, 
including high blood pressure, high blood cholesterol, 
smoking, obesity, diabetes and physical inactivity.2 Since 
the results of the Framingham Heart Study were published, 
there have been many trials for each of the CVD risk factors, 
especially elevated serum cholesterol levels.
After evaluating the major studies of cholesterol and lipids, 
the National Cholesterol Education Program (NCEP) set up 
guidelines for cholesterol management, referred to as the Adult 
Treatment Panel (ATP). The most recent panel is ATP III, which 
was released in 2001 and updated in 2004. According to ATP 
III, the primary target of cholesterol treatment is LDL-C (com-
monly referred to as “bad cholesterol”).3 The LDL-C treatment 
goal depends on an individual patient’s risk for CHD.3 The 
higher the risk for CHD, the lower the target LDL-C should be. 
For example, in high risk individuals (those who have already 
had CHD or who are at risk of CHD), LDL-C levels should 
be 100 mg/dL, while moderately high risk individuals (2 or 
more risk factors, 10-year CHD risk of 10% to 20%) should 
target their LDL-C to 130 mg/dL.3,4 If LDL-C does not reach 
the desired level, then therapeutic lifestyle changes (TLCs) such 
as physical activity and diet modification are recommended. 
Drug therapy can also be initiated.3
Only after LDL-C levels are achieved does ATP III 
recommend treating other lipids, such as non–high-density 
lipoproteins (non-HDL-C), which consist of LDL-C and very 
low-density lipoproteins (VLDL-C), as a secondary target in 
patients with TG levels of 200 to 499 mg/dL.3 Drug therapy 
can only be used to increase HDL-C, also known as “good 
cholesterol,” in patients who have metabolic syndrome and a 
history of CHD or the risk equivalent.3 The current recommen-
dations for treating LDL-C as the primary target are supported 
by most of the guidelines for cholesterol management.4–8
However, recent data suggests that HDL-C may have a 
more important role in cholesterol management than is sug-
gested by the guidelines. Furthermore, the issue of whether 
TG is an independent risk factor for CHD or should be one 
of the primary targets of therapy is controversial. To under-
stand each side in the argument, the metabolism/transport of 
cholesterol and lipoproteins in dyslipidemia and its effect 
on CHD, as well as different therapeutic targets, including 
current and future drug therapies, will be discussed.
Cholesterol and lipoprotein 
metabolism and transport
The major lipids are cholesterol, TG, and phospholipids,9 
which are used for cell membrane formation, hormone 
synthesis,10 and bile acid production. Since lipids are not 
soluble in blood, they are packaged into complexes of lipid 
and protein called lipoprotein particles.9 Lipoproteins are 
composed of phospholipids, free cholesterols, proteins 
(known as Apo lipoproteins), cholesterol esters, and TG.9 
There are 5 major classes of lipoprotein particles: chylomi-
crons, VLDL-C, intermediate density lipoproteins, LDL-C, 
and HDL-C.9
Chylomicrons are the largest lipoprotein particles, and 
transport dietary TG and cholesterols11 from the intestine9 to 
different parts of the body. The metabolism of chylomicrons is 
mediated by lipoprotein lipase (LPL), with ApoC-II acting as 
a cofactor and activator.9,11 Chylomicrons are usually present 
in the plasma for 3–6 hours after eating and are metabolized 
after 10 to 12 hours of fasting.11 After LPL metabolizes the 
chylomicrons and removes a large portion of the TG, chylo-
microns are further metabolized in the liver by hepatic lipase, 
returning ApoC-II to HDL-C.9,11 Chylomicron remnants, 
which contain Apo-E and ApoB-48, are then taken up by 
remnant receptors in the liver, which liberates free cholesterols 
intracellularly.9 During the whole process of chylomicron 
metabolism, some of the components of the chylomicron such 
as phospholipids and some Apo lipoproteins are recycled and 
used to make HDL-C.9
VLDL-C is synthesized in the liver in response to a high 
carbohydrate diet. Excess carbohydrate is converted into TG 
and transferred to nascent VLDL-C. VLDL-C delivers TG 
to adipose tissue and cardiac or skeletal muscle for storage 
and energy release by LPL. Almost all LDL-C is derived 
from VLDL-C.11
LDL-C carries about 60% to 70% of serum cholesterol.9 
It transports cholesterol from the liver to peripheral tissues. High 
levels of LDL-C are harmful, as LDL-C can build up on arte-
rial walls, leading to the formation of atherosclerotic plaques. 
The binding of LDL-C to its receptor in the liver is the major 
mechanism of removal of LDL-C from the circulation.12 An 
increase in intracellular cholesterol inhibits de novo synthesis 
of cholesterol, resulting in decreased synthesis of LDL-C 
receptor and increased activity of an enzyme that facilitates 
cholesterol storage.9
HDL-C is known to be protective against CVD, while low 
HDL-C levels increase the risk of CVD. HDL-C is produced 
in the intestine, liver and plasma as a complex of Apo A 
lipoproteins, phospholipids and cholesterol. In the plasma, 
HDL-C is converted to a cholesterol ester by the action of 
cholesterol ester transferase (LCAT). As they circulate in 
the blood stream, HDL-C particles acquire more cholesterol 
from the blood stream. In addition, HDL-C particles remove 
cholesterol through a reverse cholesterol transport process Vascular Health and Risk Management 2010:6 75
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from peripheral tissues and atheroma within the arteries to the 
liver, carrying approximately 30% of the serum cholesterol.11 
Women and individuals on estrogen therapy generally have 
higher HDL-C levels9 due to the effect of estrogen on the 
upregulation of the major components of the HDL-C particle, 
mainly ApoA-1 lipoprotein.
HDL as a risk factor for heart disease
The process known as reverse cholesterol transport involves 
removal by HDL-C of un-esterified (free) cholesterol from 
peripheral cells, such as macrophages, and delivery to the 
liver through the interaction of HDL-C with the hepatic HDL 
receptor. Several studies have shown an inverse relationship 
between blood HDL-C levels and heart disease. These studies 
show that individuals with low levels of HDL-C have worse 
CHD outcomes. Furthermore, data obtained from several 
epidemiological studies emphasize that the risk factor of low 
HDL-C levels is completely independent of LDL-C; ie, no 
matter how low the LDL-C level, a decrease in the HDL-C 
would increase the risk for coronary artery disease.
Etiology of dyslipidemia and effects 
on atherosclerosis and CHD/CVD
There are many causes of dyslipidemia, both primary and 
secondary. The primary causes of dyslipidemia are due 
mostly to genetic disorders. There are six categories of lipo-
protein disorders according to the Fredrickson-Levy-Lees 
classification: Type I (high levels of chylomicrons), Type IIa 
(high LDL-C levels), Type IIb (high LDL-C and VLDL-C 
levels), Type III (high IDL-C levels), Type IV (high VLDL-C 
levels), and Type V (high LDL-C and chylomicrons levels).9 
It is also possible that some disease states can be placed into 
more than one category of lipoprotein disorder.
The term hypertriglyceridemia usually refers to eleva-
tions in VLDL-C and chylomicrons, both of which carry 
and transport TG.5 Primary hypertriglyceridemia includes 
primary chylomicronemia, familial hypertriglyceridemia, 
familial combined hyperlipoproteinemia and familial 
dysbetalipoproteinsemia.12 Primary chylomicronemia is a 
genetic disease that is characterized by a deficiency in LPL or 
cofactor, and results in elevated chylomicrons and VLDL-C 
and severe elevation of TG, leading to acute pancreatitis.12 
Familial hypertriglyceridemia is a Type IV disorder in which 
primarily VLDL-C is affected.9 It is caused by a number of 
genetic determinants that result in insufficient removal of 
TG-rich lipoproteins.12 Familial combined hyperlipopro-
teinemia is a disorder characterized by increased levels of 
VLDL-C, LDL-C, or both. Familial dysbeta lipoproteinemia 
is a disorder characterized by increased levels of VLDL-C 
remnant and chylomicron remnant.9,12
The term hypercholesterolemia usually refers to elevated 
serum LDL-C. Primary hypercholesterolemia includes 
familial hypercholesterolemia, familial ligand-defective Apo 
lipoprotein B, and familial combined hyperlipoproteinemia. 
Primary hypercholesterolemia is a Type IIa dominant 
disorder that involves mutations in the LDL-C receptor 
gene. Homozygotes usually have a worse prognosis than 
heterozygotes. Familial ligand-defective apoliporotein B is 
also a Type IIa disorder caused by a mutation in ApoB-100 
that disrupts the binding of LDL-C to the LDL-C receptor, 
thereby decreasing metabolism of LDL-C. In both of these 
disorders, LDL-C receptor-mediated endocytosis in the liver 
is decreased, resulting in increased serum LDL-C. In addition, 
genetic evidence confirms the role of a newly discovered 
serine protease, pro-protein convertase subtilisin-like kexin 
type 9 (PCSK9), in patients suffering from autosomal-
dominant hypercholesterolemia. Three gain of function single 
nucleotide polymorphisms in the PCSK9 gene have been 
identified that increase LDL-C levels. PCSK9 destroys low 
density lipoproteins receptors (LDL-C-R) in the liver, thereby 
regulating the levels of LDL-C in plasma. Lastly, familial 
combined hyperlipoproteinemia is a Type IIb disorder that 
can cause elevated VLDL-C, LDL-C, or both.
Some rare genetic disorders can also cause low levels of 
HDL-C, ie, Tangier disease, disorders of LCAT and famil-
ial hypoalphalipoproteinemia. Tangier disease is caused 
by mutation and loss of function of ATP-binding cassette 
1 (ABCA1). ABCA1 transports cholesterol and phospholip-
ids out of cells for pickup by Apo-A1 in the circulation. In the 
absence of ABCA1, free Apo-A1 does not acquire cellular 
lipids. This results in accelerated clearance of Apo-A1 from 
plasma, leading to low HDL-C levels.13 LCAT is a lecithin 
cholesterol acyltransferase responsible for catalyzing the 
formation of cholesterol esters of HDL-C and LDL-C; thus, 
it is crucial for HDL-C formation.14 Familial hypoalphalipo-
proteinemia includes a wide range of disorders that result in 
low levels of HDL-C (usually below 35 mg/dL).
There are many secondary causes of dyslipidemia, includ-
ing disease- and medication-induced dyslipidemia. Some 
of the more common causes of hypertriglyceridemia are 
diabetes mellitus, alcohol abuse, estrogen, and obesity.9,12 
Some of the more common causes of hypercholesterolemia 
are hypothyroidism, anorexia, and excess corticosteroid 
use.9,12 Low levels of HDL-C can be caused by malnutrition, 
obesity, and drugs such as beta-blockers, anabolic steroids, 
isotretinoin, and progestins.9Vascular Health and Risk Management 2010:6 76
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High levels of LDL-C (and to a lesser extent, VLDL-C) 
result in the accumulation of LDL-C in the arterial wall, 
leading to oxidation of LDL-C.9 Oxidized LDL-C can cause 
extensive damage to the arterial wall, provoking inflamma-
tion responses, promoting coagulation, increasing the activ-
ity of mediators that cause vasoconstriction and inhibiting 
mediators that cause vasodilation.9 Oxidized LDL-C recruits 
monocytes, which enter the arterial wall and are activated 
to become macrophages. The macrophages ingest oxidized 
LDL-C through the macrophage scavenger receptor to become 
foam cells, or fatty streak. Foam cells propagate inflammatory 
responses as well as facilitate deposition of more oxidized 
LDL-C. Micro-calcification of the vascular smooth muscle 
cells will take place, which progresses to atherosclerosis. The 
fatty streak, which consists of cholesterol-filled macrophages, 
is the first stage of atherosclerosis. Plaques (deposits of fatty 
substances, cholesterol, calcium, and cell components) will 
then form and progress, gradually increasing inside the artery 
and narrowing the arterial wall, resulting in decreased flow of 
blood and oxygen to tissues. Plaques are usually kept in check 
by a fibrous cap, which protects and stabilizes the lesion. If 
the plaque ruptures, then thrombosis will occur and damage 
will spread to other areas, leading to ischemic heart disease, 
myocardial infraction (MI), stroke, peripheral arterial disease, 
other CVDs, and possibly death. Therefore, it is crucial that 
dyslipidemia, primary or secondary, is treated.
Unlike LDL-C, HDL-C is believed to help protect against 
CVD. Its protective effects are believed to be due in part 
to reverse cholesterol transport. As the name suggests, the 
reverse cholesterol transport process involves the transport of 
HDL-C from peripheral tissues and transfer to VLDL-C and 
LDL-C back to liver for secretion in the bile.9 HDL-C is also 
believed to have anti-inflammatory, anti-oxidative, platelet anti-
aggregatory, anticoagulation, and profibrolytic effects,13 which 
can help reduce damage mediated by high levels of LDL-C.
Based on the current knowledge of LDL-C and HDL-C, 
it is generally accepted that low levels of LDL-C and high 
levels of HDL-C are ideal for any patient. However, the rec-
ommendation to target both of these lipoproteins as surrogate 
goals of therapy needs to be based on the results of clinical 
studies. The same can be said for the use of pharmacotherapy 
to lower TG levels.
LDL-C and current guidelines 
for lipid management
ATP III and its update are the current lipid management guide-
lines published by the NCEP. This guideline, along with most 
of the other lipid management guidelines, recommends that 
clinicians primarily target LDL-C in treating dyslipidemia.4–8 
The LDL-C goal will depend on patient risk factors for CHD. 
According to ATP III, the risk factors for CHD are cigarette 
smoking, hypertension (140/90 mmHg), low HDL-C 
(40 mg/dL), family history of premature CHD (CHD in first 
degree relative, male 55 years old and female 65 years 
old), and age (male 45 years old and female 55 years old).3 
People who have previously had CHD (including MI, angina, 
coronary artery procedures, and myocardial ischemia) or who 
have a CHD risk equivalent (history of diabetes, noncoronary 
atherosclerotic disease such as peripheral vascular disease, 
or 2 or more risk factors for CHD with a 10 year CHD risk 
of 20%) are considered high risk patients whose LDL-C goal 
should be 100 mg/dL or 70 mg/dL.3,4
Moderately high risk refers to individuals with 2 or more 
risk factors and a 10-year risk of 10%–20%.3 Moderate risk 
refers to individuals with 2 or more risk factors and a 10-year 
risk 10%, while low risk refers to individuals with 0 to 
1 risk factors.3 The LDL-C target for moderately high risk 
and moderate risk is 130 mg/dL; the LDL-C target for 
low risk is 160 mg/dL.3 TLCs, such as decreasing intake 
of cholesterol and saturated fat in the diet, increasing intake 
of plant stanols/sterols and viscous fiber, reducing weight 
and increasing physical activity are recommended whenever 
LDL-C levels are above target.3 Drug therapy is considered 
when LDL-C is above a certain level based on individual 
risk category.3
Non-HDL-C (LDL-C + VLDL-C) becomes the second-
ary target only if an individual’s TG fall between 200 to 
499 mg/dL.3 It becomes the primary target after TG reach 
500 mg/dL, at which point the priority becomes the preven-
tion of acute pancreatitis.3 Even though the NCEP currently 
considers an HDL-C of 40 mg/dL as a risk factor (an 
increase from HDL-C 35 mg/dL in ATP II), there is no 
specific goal recommended for HDL-C. Moreover, treatment 
of individuals with low HDL-C is only considered for high 
risk patients with metabolic syndrome, and only after LDL-C 
has been treated.
ATP III is based on evidence from a number of studies, 
most of which focus on HMG-CoA reductase inhibitors, 
also known as statins, which have the greatest effect on 
LDL-C. For example, in the Primary Prevention of Acute 
Coronary Events with Lovastatin in Men and Women with 
Average Cholesterol Levels trial, it was shown that lovas-
tatin 20 to 40 mg is better than placebo in decreasing acute 
coronary events in subjects with average total cholesterol 
(TC) and LDL-C, and low HDL-C.14 Since lovastatin had 
a greater effect on LDL-C (a 25% decrease from baseline) Vascular Health and Risk Management 2010:6 77
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than TC (18% decrease), TG (15% decrease), or HDL-C 
(6% increase), the 37% relative risk reduction in major 
acute coronary events (MI, unstable angina, sudden cardiac 
death) reported in this study14 can be attributed mostly to the 
decrease in LDL-C. The same can be said for several pravas-
tatin trials, in which pravastatin 40 mg daily was shown to 
be better than placebo for primary and secondary prevention 
of coronary events.15–17 Some trials have shown that statins 
not only decrease death from cardiovascular causes, but also 
all-cause mortality.15,17 However, since the most significant 
changes are observed in LDL-C levels, the bulk of the benefit 
of statins is attributed to the reduction in LDL-C.
The Scandinavian Simvastatin Survival Study (S4) exam-
ined the independent effects of LDL-C, HDL-C, TC, and 
TG on major coronary events. S4 showed that simvastatin 
20–40 mg as compared to placebo reduces the relative risk 
of major coronary events by 34%, coronary death by 42%, 
and all cause death by 30% in subjects with angina or previ-
ous MI and relatively high TC.18 Further analysis showed 
that each additional 1% reduction in LDL-C reduces major 
coronary event (MCE) risk by 1.7% (CI 1.0% to 2.4%); each 
1% decrease in TC decreases MCE risk by 1.9 % (1.0% to 
2.8%); each 1% increase in HDL-C decreases risk by 0.8% 
(0.1% to 1.5%). No significant difference was associated 
with a 1% reduction in TG.19
In summary, ATP III contains evidenced-based rec-
ommendations supporting LDL-C as a primary target for 
therapy. Even though most of the clinical trials do not look 
at the independent effect of lowering LDL-C on CHD, most 
of the analysis supports an association between decreased 
LDL-C and reduced CHD incidence.18,20,21 Thus, the level of 
evidence that supports the recommendation of decreasing 
LDL-C to reduce CHD risk is moderately strong Grade A 
evidence based on randomized controlled trials. Despite the 
suggestion that the CHD morbidity/mortality and all-cause 
mortality benefits of LDL-C lowering drugs (especially 
statins) are due exclusively to LDL-C lowering, LDL-C 
should continue to be a primary target in treatment of patients 
with dyslipidemia.
HDL-C
There is an inverse relationship between HDL-C and CHD. 
Recent studies indicate that there is a high prevalence of 
individuals with low levels of HDL-C in the population. For 
example, in a European study of 8545 dyslipidemia patients, 
the prevalence of low levels of HDL-C (40 mg/dL in men 
and 50 mg/dL in women) was 33% in men and 40% in 
women who were treated for dyslipidemia.22 In a nationwide 
Mexican study including 15607 subjects aged 20 to 69, it was 
shown that the prevalence of low HDL-C (below 0.9 mmol 
or 35 mg/dL) was approximately 46% for men and 29% 
for women.23 This high prevalence is problematic, because 
according to the Framingham 10 year CHD risk assessment 
(derived from the Framingham Heart Study), low HDL-C is 
linked to worse CHD outcomes. It is estimated that 40% 
of coronary events occur in individuals with 40 mg/dL 
HDL-C. Moreover, according to a 12-year cohort study fol-
lowing the Framingham population, multivariable-adjusted 
relative risk for CHD (using HDL-C of 35 to 59 mg/dL as 
a reference) is 1.47 for males and 2.02 for females with 
HDL-C  35 mg/dL, and 0.56 for males and 0.58 for females 
with HDL-C  60 mg/dL.24 Data from several epidemiologi-
cal studies emphasize that the risk factor associated with low 
level HDL-C is totally independent of LDL-C; ie, no matter 
how low the LDL-C level, a decrease in the HDL-C level 
increases the risk of CHD.
Although many potential protective mechanisms for 
HDL-C have been proposed, the precise anti-atherogenic 
mechanism has yet to be resolved. The most widely accepted 
mechanism is reverse cholesterol transport. This process 
is mediated by HDL-C and involves the transfer of choles-
terol from macrophages/foam cells present in peripheral 
tissues through the blood stream to the liver, with subsequent 
metabolism of cholesterol and secretion into the bile.9 Other 
potential mechanisms include maintenance of endothelial 
integrity through increased nitric oxide (a vasodilator) 
bioavailability, promotion of endothelial cell proliferation 
and migration, and prevention of endothelial cell apoptosis.25 
Moreover, HDL-C has been shown to inhibit thrombosis, 
oxidation,25 and inflammation,26 all of which can contribute 
to atherosclerosis and CHD. However, despite current 
evidence of the potential benefits of HDL-C, clinical studies 
are needed to bolster the recommendation to target HDL-C 
in lipid management. This, however, can be a daunting task, 
because most drugs for lipid management affect more than 
one type of lipoprotein. That being said, several studies have 
analyzed the independent effects of different classes of lipo-
proteins on CHD. Table 1 summarizes the results of several 
randomized, controlled trials evaluating the effects of lipid 
drug therapy on CHD.
Analysis of the Scandinavian Simvastatin 
Survival Study18
The Scandinavian Simvastatin Survival Study was a random-
ized controled trial studying the effect of simvastatin 20 to 
40 mg on MCE such as acute MI, sudden cardiac death and Vascular Health and Risk Management 2010:6 78
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resuscitated cardiac arrest in 4,444 subjects with previous 
angina or MI.18 Simvastatin 20 to 40 mg decreased TC and 
LDL-C by 25% and 35%, respectively, and increased HDL-C 
by 8%. The relative risk of MCE was reduced by 34%, and 
the relative risk of coronary death and all-cause death was 
0.58 (CI 0.46 to 0.73) and 0.70 (CI 0.58 to 0.85), respec-
tively.18 An analysis of the relationship between lipoprotein 
changes and incidence of MCE showed that each additional 
1% reduction in LDL-C reduced MCE risk by 1.7% (CI 1.0% 
to 2.4%) and each 1% increase in HDL-C decreased risk by 
0.8% (CI 0.1% to 1.5%).19 Thus, the benefits of increasing 
HDL-C were small but statistically significant as compared to 
the benefits of decreasing LDL-C. However, one limitation of 
this study is that only baseline and first year lipoprotein and 
cholesterol measurements were taken into account; the study 
did not analyze long term changes in lipid profiles. Another 
point to consider is that statins in general exert other protective 
effects, including slightly increasing HDL-C, thus making it 
difficult to distinguish the effects of HDL-C on MCE.
Analysis of the Bezafibrate Infarction 
Prevention (BiP) trial27
The goal of the BIP trial was to determine the effect of bezafi-
brate on MCE (MI, sudden cardiac death) and mortality in 
3122 subjects with a history of MI or angina. After the original 
study ended (median follow-up 6.2 years) and study medication 
was discontinued, the patients were followed for an additional 
7.9 years. On-treatment lipid panels and cardiac mortality 
through the extended follow-up were used for analysis. The 
bezafibrate subjects were stratified into three tertiles based on 
changes in HDL-C from baseline: tertile 1 included subjects 
with HDL-C changes of less than or equal to 3.4 mg/dL; tertile 2 
included subjects with HDL-C changes between +3.41 to 
+8.02 mg/dL; and tertile 3 included any subjects with HDL-C 
changes greater than or equal to 8.03 mg/dL. There was no 
statistical difference in cardiac mortality between the bezafibrate 
and placebo groups. However, when sub-divided into tertiles, 
there was a significant difference in cardiac mortality between 
tertile 2 and 3 versus the other groups. The study concluded 
that the risk of cardiac mortality is decreased by 27% for every 
5 mg/dL increase in HDL-C.
Analysis of the Veteran Affairs 
High-density Lipoproteins  
intervention Trial (VA-HiT)28
The VA-HIT trial was a randomized, double-blind, placebo-
controlled trial designed to determine the effect of gemfi-
brozil on CHD events in men with a history of CHD who 
had low HDL-C (mean 32 mg/dL) and low LDL-C (mean 
111 mg/dL). The VA-HIT trial showed that gemfibrozil 
1200 mg per day reduces major CHD events (MI and CHD 
death) by 22% as compared to placebo during a median 
follow-up of 5.1 years. The analysis looked at lipid levels at 
4 through 18 months during the trial. The incidence of MI 
or CHD death was inversely related to HDL-C levels, and 
not related to TG and LDL-C. Some limitations of the study 
are that all the subjects were male and only lipid panels in 
the first 18 months were analyzed. In addition, changes in 
HDL-C levels in the first year (6% changes versus placebo) 
were rather small for a fibric acid derivative, leading to ques-
tions about compliance.
Analysis of the Helsinki Heart study21
The Helsinki Heart Study was a study of 4081 dyslipidemic 
men aged 40 to 55 who did not have CHD or other major dis-
abilities such as mild hypertension or non-insulin-dependent 
diabetes. Gemfibrozil 600 mg twice a day decreased the inci-
dence of CHDs, such as MI and cardiac death by 34% (CI 8.2% 
to 52.6%) without decreasing all-cause mortality. For the most 
part, lipid panel changes were responsible for the decrease in 
CHD. Changes in HDL-C and LDL-C were associated with 
CHD incidence in the treatment group while changes in TG 
were not. Estimates based on a proportional hazards model 
indicated that changes of +8% in HDL-C and –7% in LDL-C 
would reduce CHD incidence by 23% and 15%, respectively. 
Thus, a 1% increase in HDL-C can bring about a 2% to 3% 
decrease in CHD. One limitation of this study is that the sub-
jects were all male and employed by specific companies, which 
undermines extrapolation of the data.
Analysis of the Lipid Research Clinics 
Coronary Primary Prevention Trial 
(LRC-CPPT)20
The LRC-CPPT trial investigated the efficacy of cholestyr-
amine 24 g per day in 3806 asymptomatic middle aged men 
with primary hypercholesterolemia (Type II). Cholestyramine 
decreased the relative risk of CHD death and nonfatal MI 
by 19% without significantly decreasing all-cause mortality. 
The investigators proposed that the decreases in TC and 
LDL-C accounted for the majority of the benefit, while the 
small increase in HDL-C (about 3%) accounted for a 2% 
decrease in CHD.
Systematic review of HDL-C and CH29
A systematic review was performed by Dean et al on the 
effects of HDL-C on cardiovascular risk.29 A search for Vascular Health and Risk Management 2010:6 80
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articles published between January 1965 and March 2001 
yielded 51 articles for analysis (including 19 statin trials, 
6 fibrate trials, 2 resin trials, and 1 resin-niacin trial). The 
authors concluded that there is no statistically significant 
association between increased HDL-C levels and CHD 
morbidity and mortality rates, although there is a trend in 
that direction for CHD mortality (p = 0.08). However, one 
limitation of this study is that most of the articles reviewed 
were trials of statins, which only moderately increase HDL-C 
(generally 7% to 10%). This makes it more difficult to 
distinguish the effects of HDL-C on CHD morbidity and 
mortality. Furthermore, a recent review raised the concern 
that not all HDL-Cs are equally efficacious in their ability 
to decrease atherosclerosis and CHD,30 which can explain 
the range of differences between changes in HDL-C values 
and changes in CHD events. Nevertheless, a 1% increase 
in HDL-C is associated with anywhere from a 0.7 to 3% 
decrease in CHD events. In addition, increases in HDL-C 
are associated with better CHD outcomes, and the level of 
HDL-C is an independent predictor of CHD.24 The evidence 
that increasing HDL-C decreases CHD is moderately strong 
Grade A/B evidence from randomized controlled trials and 
meta-analyses, and supports consideration of targeting 
HDL-C, particularly in subjects with low levels, as well as 
LDL-C reduction.
TG
TG, like cholesterol, are one of the major lipids in the body. 
They are made up of glycerol and free fatty acids, and found 
mostly in chylomicrons and VLDL-C. Several studies have 
shown a correlation between high levels of TG and CHD.31,32 
However, it is unclear whether high levels of TG are an 
independent risk factor for CHD, and whether TG should be 
a target for therapy. The results of the Prospective Cardio-
vascular Munster (PROCAM) study support high levels of 
TG as an independent risk factor. The PROCAM study was 
a massive trial including 25,502 men and women who were 
assessed for risk factors for CHD, such as dyslipidemia, and 
followed for approximately 8 years to assess development 
of CHD.33 Multivariant analysis showed a significant age-
adjusted correlation between major coronary events and TC, 
HDL-C, LDL-C, and log-transformed TG.33
A meta-analysis of 17 prospective studies also supports 
TG as an independent risk factor for CHD.34 The univariant 
relative risk for CHD with a 1 mmol/L (89 mg/dL) increase 
in TG was 1.32 (95% CI 1.26–1.39) for men and 1.76 (95% 
CI 1.50 to 2.07) for women.34 After adjusting for variables 
such as HDL-C, cholesterol, and other risk factors, the 
relative risk was 1.14 (95% CI 1.05 to 1.28) for men and 1.37 
(95% CI 1.13 to 1.66) for women.34 However, a reduction 
in TG of 89 mg/dL seems extreme considering that normal 
levels of TG should be 150 mg/dL, according to ATP III 
guidelines. Thus, lowering of TG to a more reasonable level 
may not yield significant differences.
The S4 and VA-HIT studies did not show a significant 
association between reduced TG and CHD.19,28 The Helsinki 
Heart Study, despite documenting a 43% reduction in 
TG, concluded that an independent effect of TG was not 
relevant.35 Secondary analysis of the Multiple Risk Factor 
Intervention Trial, The Lipid Research Clinics Coronary 
Primary Prevention Trial, and The Lipid Research Clinics 
Prevalence and Mortality Follow-Up Study showed that TG 
levels in men do not predict CHD risk, although the same 
cannot be said of women.36 However, TG is a significant 
amplifier of CHD in the presence of high LDL-C and low 
HDL-C.
In summary, high levels of TG are associated with CHD 
risk, independent of other risk factors such as LDL-C and 
TC. However, the link is very weak, especially in men. The 
evidence for increasing TG as a means to decrease CHD is 
Grade A/B evidence based on randomized controlled trials 
and meta-analyses.
Current drugs for lipid management
There are several classes of drugs on the market for lipid 
management, including HMG-CoA reductase inhibitors 
(statins), bile acid sequestrants, niacin (nicotinic acid), 
fibric acid derivatives, and cholesterol absorption inhibitors. 
Each class of drug affects lipoproteins and TG to different 
degrees; therefore, specific classes of drugs are used as first-
line therapy when trying to target different lipoproteins. For 
example, because statins have the greatest effect on LDL-C, 
they are usually used as first-line therapy for high levels of 
LDL-C. On the other hand, niacin and fibric acid are more 
effective in increasing HDL-C and decreasing TG than the 
other classes of drugs. Table 2 shows the effects of each of 
the classes of drugs on lipids/lipoproteins.
HMG-CoA reductase inhibitors (statins)
The statins are the most widely used class of drug in lipid 
management. HMG-CoA reductase is the rate-limiting 
enzyme of the mevalonate pathway of cholesterol synthesis. 
Inhibition of HMG-CoA reductase disrupts cholesterol 
biosynthesis, thereby lowering total cholesterol in the body. 
The primary reason why this class of drug is so widely used 
is that it not only improves lipid profiles and CHD morbidity Vascular Health and Risk Management 2010:6 81
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and mortality, but has also been shown to decrease all-cause 
mortality in several clinical trials.15,17,18
There are a number of statins on the market. They include 
atorvastatin (Lipitor®), simvastatin (Zocor®), pravastatin 
(Pravachol®), lovastatin (Mevacor®, Altocor®), fluvastatin 
(Lescol®), and rosuvastatin (Crestor®). Some combina-
tion products including statins are atorvastatin/amlodipine 
(Caduet), simvastatin/ezetimibe (Vytorin®), pravastatin/
aspirin (Pravigard® PAC), and niacin ER/lovastatin 
(Advicor®). The oral bioavailability of statins is about 5% to 
30% due to first pass effects, and the concentration of statins 
peaks about 1 to 4 hours after oral administration.11 The 
half-life of atorvastatin and rosuvastatin is about 20 hours, 
while that of the other statins is about 1 to 4 hours, which 
may account for the relatively higher potency of atorvastatin 
and rosuvastatin.11 All of the statins are metabolized by 
cytochrome P-450 enzymes, except for pravastatin.37 Table 3 
shows typical doses needed to achieve a 30% to 40% reduc-
tion in LDL-C as well as administration guidelines and meth-
ods of metabolism for the different statins. The relationship 
between the dose of statin and its effects on lipid profile is 
not linear. In general, for each doubling of dose, there is an 
approximate 6% decrease in LDL-C.3
Statins are contraindicated in patients with unexplained 
or persistent increases in serum transaminase levels, hyper-
sensitivity to statins or any of its components, active liver 
disease, and pregnancy/lactaction.37–42 Statins should be used 
with caution when combined with niacin and fibrate (a com-
bination that would increase the risk of myopathy) and when 
used with drugs that can cause an interaction.37–42 Some of the 
adverse effects associated with statins are diarrhea, flatulence, 
heartburn, nausea, vomiting, headache, myalgia, myositis, 
rhabdomyolysis, and elevated liver enzymes.37–42 When tak-
ing a statin, the patient’s lipid panel and liver function should 
be monitored periodically.37–42 Serum creatine kinase (CK) 
should be monitored in patients experiencing muscle pain or 
who are taking other drugs that can cause myopathy.37–42 If 
patients experience muscle fatigue/weakness/ache and their 
CK is greater than 10 times the upper limit of normal, the 
statin should be discontinued as soon as possible. If CK is 
3 to 10 times the upper limit of normal, then the dose should 
be decreased, if not discontinued.43 If patients only have 
muscle symptoms without increased CK, then symptoms 
and CK should be monitored closely.43
Bile acid sequestrants or bile acid  
binding resins
Bile acid sequestrants or bile acid binding resins are positively 
charged resins that bind to negatively-charged bile acids in 
the intestine and prevent their absorption.11 To compensate 
for the loss of bile acids, the liver increases the conversion 
of cholesterol to bile acids. The conversion of cholesterol to 
bile acids reduces cholesterol in the body, resulting in a drop 
in cholesterol levels in the blood.11 However, the resins might 
also increase the production of TG, which can be problematic 
in patients with TG levels  250 mg/dL.11
The current resins on the market are cholestyramine 
(Questran®), colestipol (Colestid®), and colesevelam 
(Welchol®). These resins increase HDL-C by about 3% to 5% 
and decrease LDL-C by about 15% to 30%.3 However, when 
combined with statins, the resins can provide an additional 
12% to 16% reduction in LDL-C.3 The usual daily dose of 
cholestyramine is 4 to 16 g (powder form) given orally in 
divided doses.44 The drug should be mixed with at least 2 
to 3 ounces of water, other beverage, soup, or pulpy fruits 
before administration.44 Because cholestyramine can cause 
discoloration of teeth and erosion of enamel, it should not 
be held in mouth for a long period of time.44 The usual daily 
dose of colestipol is 5 to 20 g (powder or tablet form) given 
orally once daily or in divided doses.3 When administering 
colesipol with other drugs, other drugs should be taken at 
least 1 hour before or 4 hours after colesipol.45 The powder 
Table 2 Lipid management drugs and their effects on lipid/lipoprotein
Drug class LDL HDL TG
HMG-CoA reductase 
inhibitors (statins)3
Decrease 18%–55% increase 5%–15% Decrease 7%–30%
Bile acid sequestrants3 Decrease 15%–30% increase 3%–5% No change or increase
Niacin (nicotinic acid)3 Decrease 5%–25% increase 15%–35% Decrease 20%–50%
Fibric acid derivatives3 Decrease 5%–20%, may increase 
in patients with high TG
increase 10%–20% Decrease 20%–50%
ezetimibe51 Decrease about 18% increase about 1% Decrease about 8%
Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein;   TG, triglyceride.Vascular Health and Risk Management 2010:6 82
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form of colestipol should be mixed with at least 3 ounces of 
liquid, soup, hot cereal, or pulpy fruit before administration.45 
The usual daily dose of colesevelam is 2.6 to 3.8 g (tablet 
form) given orally in single or divided doses.3 Colesevelam 
should be taken with a meal and some liquid.46
Some of the side effects of bile acid resins are constipation, 
flatulence, indigestion, and GI distress.3 Resins can also decrease 
absorption of drugs such as statins, niacin, levothyroxine, and 
digoxin.3 Therefore, other drugs should be taken about 1 hour 
before or 4 hours after the resins (except colesevelam, which 
has a minimal effect on these other types of drug).3 Bile acid 
resins are contraindicated when TG is  400 mg/dL or if the 
patient has familial dysbeta-lipoproteinemia, and should be 
used with caution when TG  200 mg/dL.3
Nicotinic acid or niacin
Niacin is a water-soluble B vitamin that has anti-hyperlipidemic 
effects when given in large amounts. In general, niacin 
decreases LDL-C by about 5% to 25%, increases HDL-C by 
15% to 35%, and decreases TG by 20% to 50%.3 The mecha-
nism of action of niacin is still unclear, but is thought to be 
mediated by a Gi coupled receptor (GPR109A or HM74A). 
It is postulated that niacin inhibits lipolysis of TG, which 
would reduce TG synthesis due to higher levels of TG in the 
body.11 Reduced TG in turn decreases VLDL-C and therefore 
LDL-C formation. Niacin also increases HDL-C by reducing 
ApoA-I clearance.11
In a class by itself, niacin comes in several formulations, 
including immediate release (IR), sustained release (SR; 
Slo-Niacin®), and extended release (ER; Niaspan®) products. 
The usual dose of niacin is 1.2 to 3 g per day for IR, 1 to 2 g 
per day for SR, and 1 to 2 g per day for ER in single or divided 
doses.3 IR, SR, and ER products should not be substituted for 
each other because they are not the same; indeed, SR niacin 
has higher risk of liver toxicity than the other two formula-
tions.3 Niacin should be administered orally at bedtime with a 
low-fat snack to decrease gastrointestinal irritation.47 The side 
effects of niacin include flushing, pruritus, nausea, vomiting, 
gastrointestinal irritation, and rare hepatotoxicity.47 Niacin 
can also cause an approximate 5% increase in blood glucose 
levels and a 10% increase in uric acid levels.3 Aspirin or 
NSAID can be given 30 minutes before niacin to decrease 
flushing, pruritus, and gastrointestinal irritation.47 Niacin is 
contraindicated in patients with active liver disease, active 
peptic ulcer, arterial bleeding, and hypersensitivity to niacin 
products.47 It should be used with caution in patients who 
are on concomitant anticoagulants or dilators, have diabetes, 
consume a large amount of alcohol, have a history of liver 
disease, renal disease, or unstable angina, or are predisposed 
to gout.47 While on niacin, lipid profile, blood glucose levels, 
liver function, serum phosphorus, and prothrombin time/INR 
(if on anticoagulation therapy) should be monitored.47
Fibric acid derivatives
The mechanism of action of fibric acid derivatives is still 
unclear, although some researchers believe that they activate 
peroxisome proliferator activated receptors (PPARs), which 
regulate gene transcription and influence blood lipid levels.48 
The fibric acid derivatives that are currently on the market 
are gemfibrozil (Lopid®) and fenofibrate (Ticor®). The usual 
Table 3 Statin drug summary
Drug Usual dose in mg for 
30%–40% reduction 
in LDL56
Administration guidelines37–42 Metabolism37–42
Atorvastatin (Lipitor®) 10 po w or w/o food P450 CYP 3A4
Simvastatin (Zocor®) 20–40 po in evening P450 CYP 3A4
Pravastatin (Pravachol®) 40–80 po w or w/o food at anytime; when given with 
bile-acid-binding resin, give pravastatin 1 hour 
before or 4 hour after resin
isomerization, hydroxylation, 
oxidation, conjugation
Lovastatin (Mevacor®) 40–80 po take with evening meal for maximum 
bioavailability
Hydrolysis, P450  
CYP 3A4
Fluvastatin (Lescol®) 80 po take w or w/o food in the evening; if taken 
with bile-acid resin, administer fluvastatin at 
bedtime at least 2 hours after resin
75% via P450 CYP 2C9, 
5% via 2C8, 20% via 3A4
Rosuvastatin (Crestor®) 5 po w or w/o food at any time; if taken with 
aluminum and magnesium combination antacid, 
take antacid 2 hour after rosuvastatin
P450 CYP 2C9
Abbreviations: LDL, low-density lipoprotein; po, oral; w, with; w/o, without.Vascular Health and Risk Management 2010:6 83
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dose of gemfibozil is 600 mg twice daily3 and the usual dose 
of fenobibrate is 48 to 145 mg daily.49 These drugs decrease 
LDL-C by approximately 5% to 20%, increase HDL-C by 
10% to 20%, and decrease TG 20% to 50%.3 Fibric acids 
may increase LDL-C in patients with high TG, thus, they 
should not be used in patients with high LDL-C, but may be 
useful for people suffering from metabolic syndrome with 
high TG, low HDL-C, and low LDL-C. Fenofibrate should be 
taken 1 hour before or 4 to 6 hours after bile acid resin,49 and 
gemfibrozil should be taken 30 minutes before morning and 
evening meals.50 Some of the side effects of fibrate therapy are 
dyspepsia, myopathy, gallstones, and increased liver function 
test; therefore liver function test should be monitored at base-
line, 12 weeks into therapy, and periodically afterwards.3
Cholesterol absorption inhibitors
Cholesterol absorption inhibitors are a new class of drug 
whose mechanism of action involves inhibiting dietary 
cholesterol absorption. Ezetimibe (Zetia®) is currently 
the only drug available in this class. Ezetimibe alone can 
decrease LDL-C by about 18%, increase HDL-C by 1%, and 
decrease TG by 8%.51 However, when combined with a statin 
(Vytorin), ezetimibe induced greater than expected changes 
in lipid profiles.51 A recent study involving 720 patients 
with very high levels of cholesterol due to an inherited form 
of heart disease examined whether Vytorin could slow the 
growth of plaques in carotid arteries more than simvastatin 
alone. Even though Vytorin dramatically reduced LDL-C 
levels, it did not slow the progression of artery blockage 
more than generic zocor.
The usual dose of ezetimibe is 10 mg orally once daily 
with or without food.52 When administered with a bile acid 
resin, it should be taken at least 2 hours before or 4 hours 
after the resin.52 Some side effects of ezetimibe are diarrhea, 
abdominal pain, arthralgia, backache, myalgia, headache, 
sinusitis, hepatitis, anaphylaxis, myopathy and rhabdomy-
olysis (rare).52 Ezetimibe is contraindicated in active liver 
disease or persistently elevated liver enzyme (when taken 
with a statin).52 Caution should be used when giving ezeti-
mibe to children under 10 years old and patients with hepatic 
insufficiency.52 While on ezetimibe, lipid panels should be 
monitored. Monitoring of serum CK is recommended in 
patients complaining of muscle pain or who are at high risk 
of developing myopathy or rhabdomyolysis.52
Future drug therapy
Many studies are underway to identify better drugs for treat-
ing abnormal lipid levels. Since the statins have proven to 
be the drug of choice for decreasing LDL-C, the focus of 
future lipid management therapy is to find new agents that 
increase HDL-C with minimal side effects. One potential 
mechanism of increasing HDL-C is inhibition of cholesteryl 
ester transfer protein (CETP). CETP is synthesized in the 
liver, and transfers cholesteryl esters from HDL-C to LDL-C 
or TG-rich lipoproteins in exchange for TG.11 After addition 
of TG to HDL-C, HDL-C is more readily catabolized in 
the liver.11 Partial inhibition of CETP is associated with an 
increase in HDL-C of up to 100%, and may also decrease 
LDL-C levels. Current CETP inhibitors in development are 
JTT-705, torcetrapib,11 and anacetrapib. Clinical trials of 
torcetrapib have been terminated due to increased mortal-
ity associated with the torcetrapib/atorvastatin group as 
compared to the atrovastatin group in Phase 3 studies. The 
reason for this increase in mortality is unclear; however, 
certain side effects such as increased blood pressure have 
been noted. Since the three drugs employ different mecha-
nisms to inhibit CETP, JTT-705 and anacetrapib still have 
the potential to be marketed.
Another potential target for raising HDL-C levels is 
augmenting ApoA-I levels (an important protein in HDL-C). 
Overexpression of ApoAI or infusion of ApoA-I in animal 
models increases HDL-C levels and decreases atherosclerosis. 
The two main ApoA-I peptides currently under investigation are 
the ApoA-IMilano complex and the D-4F peptide. Other possible 
targets include PPAR agonists, such as the glitazones, which are 
known to have modest HDL-C-boosting effects, although their 
main action is in reducing insulin resistance. PPAR agonists 
have been postulated to increase macrophage cholesterol efflux 
through increased levels of ABCA1 and ABCG1. Currently, 
niacin is considered the most effective pharmacologic agent 
for raising HDL-C. While the molecular mechanism of niacin’s 
effect is not known, a G protein–coupled receptor called 
GPR109A (HM74A) has been identified as a niacin receptor. 
It is expressed primarily in adipocytes and its activation results 
in reduced release of fatty acids from adipose. This may explain 
niacin’s effects on plasma TG, but fails to explain its effects on 
HDL-C. Compounds that specifically target the activation of 
GPR109A are currently in clinical trials. Finally, inhibition of 
endolipase, which hydrolyzes HDL-C and decreases HDL-C 
levels, is another potential approach.53
Conclusion
Cardiovascular disease is the number one cause of death in 
the United States.1 Since the Framingham Heart Study, which 
identified high cholesterol as one of the risk factors for CHD, 
there have been many trials studying the effect of changes Vascular Health and Risk Management 2010:6 84
Lin et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
in lipid profiles on CHD. These studies have also elucidated 
the functions, metabolism, and transport of lipids as part of 
normal physiology. Many primary and secondary causes of 
dyslipidemia have been identified. We now know that high 
LDL-C levels are associated with increased risk of CHD, and 
high HDL-C levels are associated with reduced risk of CHD. 
The current ATP III guidelines for lipid management target 
LDL-C as the primary surrogate goal for lipid management. 
This recommendation is supported by many clinical trials. 
However, the ATP III guideline neglects to identify HDL-C 
as a target for therapy. Analysis of major randomized control 
trials shows that each 1% increase in HDL-C is associated 
with a 0.7% to 3% decrease in CHD.19–21,27,28 Thus, the risk 
factor associated with low HDL-C should be considered as 
an major independent risk factor for CHD.29
Unlike LDL-C and HDL-C, the effects of reduced TG 
levels alone on CHD are less apparent, but reduced TG may 
be an important amplifier in the presence of dyslipedmic fac-
tors. Even though elevated TG might be an independent risk 
factor for CHD, a large reduction in TG is needed to show a 
difference, especially in the male population. New treatments 
using a combination of drugs targeting both LDL-C and 
HDL-C along with TG management would have a superior 
outcome for dyslipidemia therapy and decrease mortality 
due to CHD/CVD.
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